In short
A new clinical trial is investigating the use of Mitazalimab, a CD40 antibody, in combination with Irreversible Electroporation (IRE) for patients with locally advanced pancreatic cancer. This innovative approach aims to enhance the immune system's response against cancer cells while minimizing side effects. The study focuses on the safety and effectiveness of this treatment combination, offering hope for improved outcomes in pancreatic cancer patients.
At a glance
- Study Type
- Phase I clinical trial
- Treatment
- Intratumoral Mitazalimab (CD40 antibody) with Irreversible Electroporation (IRE)
- Condition
- Locally advanced pancreatic cancer
- Primary Outcome
- Safety and tolerability
- Secondary Outcomes
- Progression-free survival, Overall survival, Systemic immune effects
- Administration Method
- Intratumoral injection following IRE procedure
- Study Design
- Dose escalation (Phase IA) followed by expansion cohort (Phase IB)
What is Mitazalimab?
Mitazalimab is a type of medication known as a CD40 antibody. It is currently being studied as a potential treatment for locally advanced pancreatic cancer. Locally advanced pancreatic cancer refers to tumors that have not spread to distant parts of the body but cannot be surgically removed due to their size or location.
How Mitazalimab Works
Mitazalimab works by targeting and stimulating a specific receptor in the immune system called CD40. This receptor plays a crucial role in helping the immune system recognize and fight cancer cells. By activating CD40, mitazalimab aims to enhance the body's natural ability to combat pancreatic cancer.
Treatment Approach: Combining Mitazalimab with IRE
In the current clinical trial, mitazalimab is being used in combination with a procedure called Irreversible Electroporation (IRE). IRE is a form of non-thermal ablation, which means it destroys cancer tissue without using heat. Here's how the combined treatment works:
- IRE Procedure: First, doctors perform IRE on the pancreatic tumor. This procedure uses short, strong electric pulses to destroy cancer cells and create inflammation in the tumor area.
- Mitazalimab Injection: Five minutes after completing IRE, mitazalimab is injected directly into the center of the treated tumor area.
- Immune Response: The combination of IRE and mitazalimab is designed to stimulate a strong immune response against the cancer cells.
Current Clinical Trial
Mitazalimab is currently being studied in a Phase I clinical trial for patients with locally advanced pancreatic cancer. The trial aims to determine:
- The safety and tolerability of intratumoral (injected directly into the tumor) mitazalimab when combined with IRE.
- The most appropriate dose of mitazalimab for future studies.
- Preliminary evidence of the treatment's effectiveness.
Potential Benefits
The researchers hope that this new approach of combining mitazalimab with IRE may offer several potential benefits:
- Enhanced Immune Effects: The combination may boost the immune-stimulating effects of IRE, potentially leading to a stronger anti-cancer response.
- Reduced Risk of Recurrence: By enhancing the immune response, the treatment may help lower the chances of cancer coming back.
- Fewer Side Effects: Injecting mitazalimab directly into the tumor (instead of into the bloodstream) may reduce system-wide side effects while potentially increasing its effectiveness.
Safety and Side Effects
As this is a Phase I clinical trial, one of the main goals is to assess the safety and tolerability of the treatment. The researchers will be closely monitoring for any side effects or adverse events that may occur. Some potential side effects that will be watched for include:
- Cytokine Release Syndrome: A condition where the immune system becomes overly activated, potentially causing symptoms like fever, nausea, and fatigue.
- Other immune-related side effects that may occur with immunotherapy treatments.
It's important to note that as this is an early-stage clinical trial, the full range of potential side effects is not yet known. Patients participating in the trial will be closely monitored for any unexpected reactions.